#United States #Denver #High Tide #NuLeaf Naturals #Medicare CBD

NuLeaf Naturals Enters Medicare CBD Pilot Program

High Tide Inc. has made an important announcement regarding its subsidiary, NuLeaf Naturals. As of today, NuLeaf Naturals is pursuing participation in the U.S. Centers for Medicare & Medicaid Services (CMS) Innovation Center's Beneficiary Engagement Incentive (BEI) pilot program. This initiative marks a pivotal moment for integrating hemp-derived CBD products into federal healthcare frameworks.

Significance of the Initiative

The CMS BEI pilot program aims to provide eligible hemp-derived CBD products to Medicare beneficiaries at no cost, a breakthrough for the accessibility of cannabinoid therapies. Qualified organizations under specific models, such as Accountable Care Organizations (ACOs) and oncology practices, can offer these products without charging beneficiaries, potentially covering up to $500 annually per individual.

As the program unfolds, CMS has hinted at expansion opportunities, possibly including participants from the Long-term Enhanced ACO Design Model starting January 2027, which signals a broader inclusion of hemp-derived product applications.

NuLeaf Naturals, based in Denver, Colorado, is positioned to fill a vital role in this initiative. Established in 2014, the company is recognized for its commitment to producing high-quality cannabinoid products through its cGMP-certified and FDA-registered facilities. They expect to align their product portfolio with the pilot program's compliance needs, which will include THC-free and broad-spectrum CBD options.

Building on a Strong Foundation

NuLeaf’s engagement with the CMS pilot program is not out of the blue. The company is leveraging its strategic foundation by active participation in the National Compassionate Care Council (NCCC), consisting of healthcare organizations advocating for improved patient access to cannabinoid therapies.

High Tide’s CEO, Raj Grover, emphasized the historic nature of this pilot program for the U.S. CBD industry and particularly for Medicare beneficiaries who now stand to benefit access to hemp-derived therapies. According to Grover, “This program has the potential to become a meaningful growth driver for High Tide’s U.S. CBD business.”

The Path Forward

The broader context for this initiative can be traced back to an Executive Order issued by the U.S. President on December 18, 2025, which encouraged re-evaluation of cannabis scheduling and called for enhanced access to full-spectrum CBD products. Dr. Mehmet Oz, the CMS Administrator, affirmed during this announcement that eligible hemp-derived CBD products could be provided through physician recommendations.

Facilities participating in the pilot must submit detailed plans to CMS, including information about product types, dosing, and eligibility criteria, while ensuring compliance with various safeguards. Interestingly, Medicare won’t directly cover these products; instead, costs will be absorbed by the participating organizations.

The CMS has also characterized the BEI program as a valuable opportunity to gather clinical evidence regarding hemp-derived CBD use in structured medical contexts, paving the way for potential future reimbursements as more data is collected.

Conclusion

High Tide and its subsidiary, NuLeaf Naturals, are positioned to significantly impact the cannabinoid landscape, particularly in healthcare. As the realities of cannabinoid therapies evolve within the regulatory framework and healthcare models, it will be crucial to monitor the developments emanating from this pilot program. As more information becomes available, both industry players and consumers alike eagerly anticipate how this initiative will reshape access to CBD therapies in the United States.